2,584 Shares in Danaher Corporation $DHR Bought by Camelot Portfolios LLC

Camelot Portfolios LLC bought a new stake in Danaher Corporation (NYSE:DHR) during the second quarter, Holdings Channel reports. The fund bought 2,584 shares of the conglomerate’s stock, valued at approximately $492,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. High Note Wealth LLC lifted its stake in shares of Danaher by 19.2% in the 4th quarter. High Note Wealth LLC now owns 292 shares of the conglomerate’s stock valued at $67,000 after purchasing an additional 47 shares in the last quarter. First Command Advisory Services Inc. increased its position in Danaher by 4.4% during the 4th quarter. First Command Advisory Services Inc. now owns 1,104 shares of the conglomerate’s stock worth $253,000 after purchasing an additional 47 shares in the last quarter. GW&K Investment Management LLC increased its position in Danaher by 8.4% during the 4th quarter. GW&K Investment Management LLC now owns 605 shares of the conglomerate’s stock worth $138,000 after purchasing an additional 47 shares in the last quarter. Kestra Private Wealth Services LLC raised its holdings in Danaher by 0.3% in the third quarter. Kestra Private Wealth Services LLC now owns 15,421 shares of the conglomerate’s stock valued at $3,057,000 after buying an additional 48 shares during the period. Finally, Gabelli Funds LLC raised its holdings in Danaher by 0.3% in the fourth quarter. Gabelli Funds LLC now owns 18,981 shares of the conglomerate’s stock valued at $4,345,000 after buying an additional 50 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on DHR. HSBC decreased their price objective on shares of Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Evercore reissued an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research note on Monday, July 6th. TD Cowen reduced their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Citigroup initiated coverage on shares of Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 price target for the company. Finally, DZ Bank assumed coverage on Danaher in a report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Stock Up 0.2%

NYSE DHR opened at $216.41 on Monday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The business has a 50 day moving average price of $199.46 and a two-hundred day moving average price of $192.35. The stock has a market cap of $152.13 billion, a PE ratio of 38.44, a P/E/G ratio of 2.69 and a beta of 0.78.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the firm posted $0.77 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.